$CELG Company News Dow industrials suffer worst
Post# of 144497
Posted On: 01/21/2014 10:29:07 AM
$CELG Company News
Dow industrials suffer worst drop since Sept. 20: Stock market live blog recap 4:41 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Celgene's 2014 guidance falls below analyst views 12:19 p.m. Jan. 13, 2014 - MarketWatch.com
Clovis Oncology, seen as 'next ICPT,' jumps 5% 9:47 a.m. Jan. 13, 2014 - Victor Reklaitis
Intercept, Celgene on move amid J.P. Morgan event 9:20 a.m. Jan. 13, 2014 - Victor Reklaitis
Epizyme shares surge 65% after cancer therapy hits milestone 11:06 a.m. Jan. 7, 2014 - Russ Britt
Sirius soars; Twitter tumbles on downgrade 3:50 p.m. Jan. 6, 2014 - Wallace Witkowski
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
Sorry, haters: Unloved stocks had a great year 7:41 a.m. Dec. 30, 2013 - Brett Arends
These S&P winners have room to grow in 2014 6:00 a.m. Dec. 23, 2013 - Jeff Reeves
Two growth stocks that look ready to fly 1:29 p.m. Dec. 12, 2013 - The Trading Deck
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
What the worst advisers are recommending 1:16 p.m. Nov. 21, 2013 - Mark Hulbert
Top performers’ top November bets 11:01 p.m. Nov. 3, 2013 - Mark Hulbert
Celgene raises earnings outlook as sales climb 7:27 a.m. Oct. 24, 2013 - MarketWatch.com
A bull market as typical as any other 11:23 a.m. Oct. 22, 2013 - The Trading Deck
No shortcut to innovation 7:30 a.m. Oct. 2, 2013 - Mark Hulbert
Market uptrend bends, without cracking 11:55 a.m. Oct. 1, 2013 - Michael Ashbaugh
Market technicals bend, without cracking 11:38 a.m. Oct. 1, 2013 - Michael Ashbaugh
Of keg parties and Big Ben 11:29 a.m. Sept. 19, 2013 - The Trading Deck
Updates, advisories and surprises 4:31 p.m. July 25, 2013 - MarketWatch
Forecasting Earnings Growth And Profitability In The Biopharmaceutical Industry 7:19 a.m. Today - Seeking Alpha
Positive Oncology News Lifts OncoMed - Analyst Blog 5:10 p.m. Jan. 20, 2014 - Zacks.com
Gilead Is Not Done; There Is Potentially 50% More Upside This Year 5:32 p.m. Jan. 17, 2014 - Seeking Alpha
Several IBD 50 Medical Companies Seen Posting Strong Q4 Profit Gains 5:16 p.m. Jan. 17, 2014 - Investors Business Daily
J.P. Morgan Confab Focus Reminds Us Upside Remains In Biotech 3:30 p.m. Jan. 17, 2014 - TheStreet.com
My Five Favorite Bio-Pharma Stocks from the J.P. Morgan Healthcare Conference 1:50 p.m. Jan. 17, 2014 - TheStreet.com
Celgene Corporation Retains Buy Recommendation 9:00 a.m. Jan. 17, 2014 - TheStreet.com
Stocks 2014: Investing For Growth - The Power And Protection Of High Compounding Earnings Growth - Part 2 1:19 p.m. Jan. 16, 2014 - Seeking Alpha
CELG February 14th Options Begin Trading 11:20 a.m. Jan. 16, 2014 - TheStreet.com
Biotech Stock Roundup: Intercept Pharma Grabs the Limelight - Analyst Blog 9:31 a.m. Jan. 15, 2014 - Zacks.com
Biogen, Celgene Lead 5 Top Large-Cap Drugmakers 7:05 a.m. Jan. 15, 2014 - Investors Business Daily
Jim Cramer's 6 Stocks in 60 Seconds: GIS CLF BMRN YUM CELG SSYS (Update 1) 5:21 p.m. Jan. 14, 2014 - TheStreet.com
Celgene Provides Rosy Long-term Projection - Analyst Blog 12:00 p.m. Jan. 14, 2014 - Zacks.com
Merck Turnaround Is Working Out Well 11:15 a.m. Jan. 14, 2014 - Barrons.com
Jim Cramer's 'Mad Money' Recap: Is the Downturn Serious? 8:09 p.m. Jan. 13, 2014 - TheStreet.com
Facebook, Other Big Cap 20 Leaders Fall In Low Volume 5:49 p.m. Jan. 13, 2014 - Investors Business Daily
Biotech Stocks Back On Top, Led By Biogen, Alexion 5:07 p.m. Jan. 13, 2014 - Investors Business Daily
Celgene Corporation (CELG): Today's Featured Health Care Laggard 5:01 p.m. Jan. 13, 2014 - TheStreet.com
It's Lunchtime at the J.P. Morgan Healthcare Confab. Here's What I Learned So Far 4:12 p.m. Jan. 13, 2014 - TheStreet.com
Celgene Raises Long-Term Guidance, But Q4 Falls Short 12:28 p.m. Jan. 13, 2014 - Investors Business Daily
Celgene Corporation Announces 2014 Financial Outlook and Preliminary 2013 Results 11:29 a.m. Jan. 13, 2014 - BusinessWire - BZX
Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan 8:00 a.m. Jan. 7, 2014 - PR Newswire
ABRAXANE(R) Plus gemcitabine Receives European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer 6:01 a.m. Jan. 7, 2014 - BusinessWire
Critical Alerts For Google, Celgene, Salesforce.com, Chesapeake Energy, and Endo Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Jan. 3, 2014 - PR Newswire
Celgene Corporation to Present at the 32nd Annual J.P. Morgan Healthcare Conference 8:29 a.m. Jan. 2, 2014 - BusinessWire
Presentation of Clinical Study Data, Prestigious Accolades, and Acquisitions - Research Report on Celgene, UnitedHealth, AstraZeneca, Mylan, and Valeant 8:00 a.m. Dec. 25, 2013 - PR Newswire
Clinical Study Data Presentation, Product Launches, Technology Deployments, and Stock Price Movements - Research Report on Celgene, Mylan, Valeant, Health Management, and CareFusion 8:00 a.m. Dec. 17, 2013 - PR Newswire
Atara Biotherapeutics Secures $38.5 Million Series B Financing 7:00 a.m. Dec. 17, 2013 - BusinessWire
Agios Advances Cancer Metabolism Collaboration with Celgene 8:16 a.m. Dec. 11, 2013 - BusinessWire
Studies Evaluating REVLIMID(R) (Lenalidomide) in Lymphoma Presented at ASH 7:00 p.m. Dec. 10, 2013 - BusinessWire
Two Studies Highlight Retrospective Analyses of Phase III Study of POMALYST(R)/IMNOVID(R) (Pomalidomide) in Previously Treated Multiple Myeloma Patients Presented at ASH 8:30 a.m. Dec. 10, 2013 - BusinessWire
REVLIMID(R) (lenalidomide)-Treated Patients with Deletion-5q MDS Who Achieve Transfusion-Independence of At Least 26 Weeks and AML-Free Survival Associated with Cytogenetic Response 7:30 p.m. Dec. 9, 2013 - BusinessWire
Stock Price Movements, Completed Acquisitions, and New Clinical Studies - Research Report on UnitedHealth Group, Mylan, St. Jude Medical, and Cigna 8:00 a.m. Dec. 9, 2013 - PR Newswire
First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH 9:37 p.m. Dec. 7, 2013 - BusinessWire
Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin 9:05 a.m. Dec. 4, 2013 - PR Newswire
OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients 7:30 a.m. Dec. 3, 2013 - GlobeNewswire
Positive Opinion, Stock Price Movement, and Executive Appointments - Research Report on Celgene, Sirona, Centene, Fresenius Medical Care, and PerkinElmer 8:00 a.m. Nov. 28, 2013 - PR Newswire
Critical Alerts For American Express, Celgene, Altera, JC Penney, and Coach Released By InvestorsObserver 9:31 a.m. Nov. 25, 2013 - PR Newswire
Today's Research: Celgene Corp., Forest Laboratories Inc., Edwards Lifesciences Corp., and Peregrine Pharma Inc. 1:30 p.m. Nov. 22, 2013 - PR Newswire
Celgene Receives Positive CHMP Opinion for ABRAXANE(R) in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer 7:25 a.m. Nov. 22, 2013 - BusinessWire
Dow industrials suffer worst drop since Sept. 20: Stock market live blog recap 4:41 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Celgene's 2014 guidance falls below analyst views 12:19 p.m. Jan. 13, 2014 - MarketWatch.com
Clovis Oncology, seen as 'next ICPT,' jumps 5% 9:47 a.m. Jan. 13, 2014 - Victor Reklaitis
Intercept, Celgene on move amid J.P. Morgan event 9:20 a.m. Jan. 13, 2014 - Victor Reklaitis
Epizyme shares surge 65% after cancer therapy hits milestone 11:06 a.m. Jan. 7, 2014 - Russ Britt
Sirius soars; Twitter tumbles on downgrade 3:50 p.m. Jan. 6, 2014 - Wallace Witkowski
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
Sorry, haters: Unloved stocks had a great year 7:41 a.m. Dec. 30, 2013 - Brett Arends
These S&P winners have room to grow in 2014 6:00 a.m. Dec. 23, 2013 - Jeff Reeves
Two growth stocks that look ready to fly 1:29 p.m. Dec. 12, 2013 - The Trading Deck
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
What the worst advisers are recommending 1:16 p.m. Nov. 21, 2013 - Mark Hulbert
Top performers’ top November bets 11:01 p.m. Nov. 3, 2013 - Mark Hulbert
Celgene raises earnings outlook as sales climb 7:27 a.m. Oct. 24, 2013 - MarketWatch.com
A bull market as typical as any other 11:23 a.m. Oct. 22, 2013 - The Trading Deck
No shortcut to innovation 7:30 a.m. Oct. 2, 2013 - Mark Hulbert
Market uptrend bends, without cracking 11:55 a.m. Oct. 1, 2013 - Michael Ashbaugh
Market technicals bend, without cracking 11:38 a.m. Oct. 1, 2013 - Michael Ashbaugh
Of keg parties and Big Ben 11:29 a.m. Sept. 19, 2013 - The Trading Deck
Updates, advisories and surprises 4:31 p.m. July 25, 2013 - MarketWatch
Forecasting Earnings Growth And Profitability In The Biopharmaceutical Industry 7:19 a.m. Today - Seeking Alpha
Positive Oncology News Lifts OncoMed - Analyst Blog 5:10 p.m. Jan. 20, 2014 - Zacks.com
Gilead Is Not Done; There Is Potentially 50% More Upside This Year 5:32 p.m. Jan. 17, 2014 - Seeking Alpha
Several IBD 50 Medical Companies Seen Posting Strong Q4 Profit Gains 5:16 p.m. Jan. 17, 2014 - Investors Business Daily
J.P. Morgan Confab Focus Reminds Us Upside Remains In Biotech 3:30 p.m. Jan. 17, 2014 - TheStreet.com
My Five Favorite Bio-Pharma Stocks from the J.P. Morgan Healthcare Conference 1:50 p.m. Jan. 17, 2014 - TheStreet.com
Celgene Corporation Retains Buy Recommendation 9:00 a.m. Jan. 17, 2014 - TheStreet.com
Stocks 2014: Investing For Growth - The Power And Protection Of High Compounding Earnings Growth - Part 2 1:19 p.m. Jan. 16, 2014 - Seeking Alpha
CELG February 14th Options Begin Trading 11:20 a.m. Jan. 16, 2014 - TheStreet.com
Biotech Stock Roundup: Intercept Pharma Grabs the Limelight - Analyst Blog 9:31 a.m. Jan. 15, 2014 - Zacks.com
Biogen, Celgene Lead 5 Top Large-Cap Drugmakers 7:05 a.m. Jan. 15, 2014 - Investors Business Daily
Jim Cramer's 6 Stocks in 60 Seconds: GIS CLF BMRN YUM CELG SSYS (Update 1) 5:21 p.m. Jan. 14, 2014 - TheStreet.com
Celgene Provides Rosy Long-term Projection - Analyst Blog 12:00 p.m. Jan. 14, 2014 - Zacks.com
Merck Turnaround Is Working Out Well 11:15 a.m. Jan. 14, 2014 - Barrons.com
Jim Cramer's 'Mad Money' Recap: Is the Downturn Serious? 8:09 p.m. Jan. 13, 2014 - TheStreet.com
Facebook, Other Big Cap 20 Leaders Fall In Low Volume 5:49 p.m. Jan. 13, 2014 - Investors Business Daily
Biotech Stocks Back On Top, Led By Biogen, Alexion 5:07 p.m. Jan. 13, 2014 - Investors Business Daily
Celgene Corporation (CELG): Today's Featured Health Care Laggard 5:01 p.m. Jan. 13, 2014 - TheStreet.com
It's Lunchtime at the J.P. Morgan Healthcare Confab. Here's What I Learned So Far 4:12 p.m. Jan. 13, 2014 - TheStreet.com
Celgene Raises Long-Term Guidance, But Q4 Falls Short 12:28 p.m. Jan. 13, 2014 - Investors Business Daily
Celgene Corporation Announces 2014 Financial Outlook and Preliminary 2013 Results 11:29 a.m. Jan. 13, 2014 - BusinessWire - BZX
Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan 8:00 a.m. Jan. 7, 2014 - PR Newswire
ABRAXANE(R) Plus gemcitabine Receives European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer 6:01 a.m. Jan. 7, 2014 - BusinessWire
Critical Alerts For Google, Celgene, Salesforce.com, Chesapeake Energy, and Endo Pharmaceuticals Released By InvestorsObserver 9:31 a.m. Jan. 3, 2014 - PR Newswire
Celgene Corporation to Present at the 32nd Annual J.P. Morgan Healthcare Conference 8:29 a.m. Jan. 2, 2014 - BusinessWire
Presentation of Clinical Study Data, Prestigious Accolades, and Acquisitions - Research Report on Celgene, UnitedHealth, AstraZeneca, Mylan, and Valeant 8:00 a.m. Dec. 25, 2013 - PR Newswire
Clinical Study Data Presentation, Product Launches, Technology Deployments, and Stock Price Movements - Research Report on Celgene, Mylan, Valeant, Health Management, and CareFusion 8:00 a.m. Dec. 17, 2013 - PR Newswire
Atara Biotherapeutics Secures $38.5 Million Series B Financing 7:00 a.m. Dec. 17, 2013 - BusinessWire
Agios Advances Cancer Metabolism Collaboration with Celgene 8:16 a.m. Dec. 11, 2013 - BusinessWire
Studies Evaluating REVLIMID(R) (Lenalidomide) in Lymphoma Presented at ASH 7:00 p.m. Dec. 10, 2013 - BusinessWire
Two Studies Highlight Retrospective Analyses of Phase III Study of POMALYST(R)/IMNOVID(R) (Pomalidomide) in Previously Treated Multiple Myeloma Patients Presented at ASH 8:30 a.m. Dec. 10, 2013 - BusinessWire
REVLIMID(R) (lenalidomide)-Treated Patients with Deletion-5q MDS Who Achieve Transfusion-Independence of At Least 26 Weeks and AML-Free Survival Associated with Cytogenetic Response 7:30 p.m. Dec. 9, 2013 - BusinessWire
Stock Price Movements, Completed Acquisitions, and New Clinical Studies - Research Report on UnitedHealth Group, Mylan, St. Jude Medical, and Cigna 8:00 a.m. Dec. 9, 2013 - PR Newswire
First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH 9:37 p.m. Dec. 7, 2013 - BusinessWire
Biotech Briefing: Advancing Biotechs Forging Ahead With Breaking News Developments: Alliqua, OncoMed Pharmaceuticals, EnteroMedics, Unilife, Amarin 9:05 a.m. Dec. 4, 2013 - PR Newswire
OncoMed and Celgene Announce Strategic Collaboration Advancing Multiple Anti-Cancer Stem Cell Therapeutics to Offer Potential Benefits to Cancer Patients 7:30 a.m. Dec. 3, 2013 - GlobeNewswire
Positive Opinion, Stock Price Movement, and Executive Appointments - Research Report on Celgene, Sirona, Centene, Fresenius Medical Care, and PerkinElmer 8:00 a.m. Nov. 28, 2013 - PR Newswire
Critical Alerts For American Express, Celgene, Altera, JC Penney, and Coach Released By InvestorsObserver 9:31 a.m. Nov. 25, 2013 - PR Newswire
Today's Research: Celgene Corp., Forest Laboratories Inc., Edwards Lifesciences Corp., and Peregrine Pharma Inc. 1:30 p.m. Nov. 22, 2013 - PR Newswire
Celgene Receives Positive CHMP Opinion for ABRAXANE(R) in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer 7:25 a.m. Nov. 22, 2013 - BusinessWire
(0)
(0)Scroll down for more posts ▼